Product Development Pipeline

RegeneRx has initiated 5 clinical trials to develop 3 product candidates in our pipeline. The product candidates are all Tβ4-based peptides and have been formulated to optimize the clinical potential in various medical indications, all with unmet needs. All clinical studies are dose-escalating, randomized, double-blinded and placebo-controlled.

	Pressure Ulcers (COMPLETED) Venous Stasis Ulcers Epidermolysis Bullosa Diabetic Foot Ulcers Burns
	Corneal Wounds (CLOSED) Recurrent Corneal Erosions Corneal Surgeries Sjögren’s Dry Eye
	Acute Myocardial Infarction Ischemic Stroke Ischemic Renal Disease Crohn's/Ulcerative Colitis Epidermolysis Bullosa Multiple Sclerosis
	Cystic Fibrosis Bronchiectasis

For full updated detail of each RegeneRx clinical trial go to www.clinicaltrials.gov or click on the highlighted indication above for each trial.